Allergan, Inc., and Inamed Corporation, In the Matter of

Last Updated:
In the Matter of Allergan, Inc., and Inamed Corporation
FTC Matter/File Number:

061 0031

Docket Number:


Enforcement Type:

Part 2 Consents

Case Summary

The consent order requires that Allergan and Inamed divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle charges that Allergan’s $3.2 billion purchase of Inamed would reduce competition and force consumers to pay higher prices for botulinum toxin type A products. Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.- based manufacturer.